vascuCAP vs ClearRead CT
Similar category, different focus. These tools serve overlapping but distinct needs.
Comparability 65/100
Comparability is an AI-graded 0–100 score of how directly these two tools compete — higher means a more apples-to-apples comparison.
AI Verdict
Tool A (vascuCAP) specializes in detailed, histologically-validated plaque quantification and characterization from CT angiography to assess cardiovascular risk and guide treatment decisions. Tool B (ClearRead CT) offers coronary artery calcification scoring from ungated, non-contrast CTs, but its primary differentiating feature is its advanced AI for pulmonary nodule detection and characterization. Therefore, vascuCAP is better suited for in-depth plaque vulnerability analysis, while ClearRead CT is ideal for comprehensive cardiothoracic screening that includes both lung nodule detection and general CAC assessment.
Reviewed by Pouyan Golshani, MD — Interventional Radiologist
Frequently Asked Questions
vascuCAP (now ElucidVivo/PlaqueIQ) is designed for non-invasive CT angiography analysis, quantifying plaque composition and assessing cardiovascular risk to optimize treatment decisions. ClearRead CT enhances pulmonary nodule detection and performs coronary artery calcification (CAC) analysis on general CT scans, including ungated, non-contrast CTs for CAC scoring.
vascuCAP provides histologically-validated quantification and characterization of specific plaque components such as lipid-rich necrotic core, calcification, non-calcified matrix, and intraplaque hemorrhage from CT angiograms. ClearRead CT offers coronary artery calcification (CAC) scoring from ungated, non-contrast CTs, but does not provide the detailed plaque component analysis of vascuCAP.
Both vascuCAP and ClearRead CT support Cardiology and Radiology. Additionally, vascuCAP is relevant for Vascular Surgery, while ClearRead CT's features for pulmonary nodule detection make it valuable for Pulmonology.
vascuCAP aims to optimize treatment decisions through precise plaque quantification and risk stratification for stroke and heart attack, with studies suggesting improved accuracy in stroke prediction. ClearRead CT claims reduced reading times (up to 36%) and improved detection accuracy (29% reduction in missed actionable nodules) for pulmonary nodules.
ClearRead CT offers coronary artery calcification (CAC) scoring, which is a recognized predictor of future cardiac events and can be used for cardiovascular risk assessment. However, it does not provide the detailed, histologically-validated quantification of specific plaque components like lipid-rich necrotic core or intraplaque hemorrhage that vascuCAP offers for comprehensive cardiovascular risk stratification.